| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Department of Microbiology, Biochemistry, and Immunology, Morehouse School of Medicine, Atlanta, GA 30310;
Institute of Microbiology and Genetics, University of Vienna, Vienna, Austria;
Center for Cancer Research and Therapeutic Development, Clark Atlanta University, Atlanta, GA 30314; and
National Center for Infectious Disease, Centers for Disease Control and Prevention, Atlanta, GA 30333
The administration of an efficacious vaccine is the most effective long-term measure to control the oculogenital infections caused by Chlamydia trachomatis in humans. Chlamydia genome sequencing has identified a number of potential vaccine candidates, and the current challenge is to develop an effective delivery vehicle for induction of a high level of mucosal T and complementary B cell responses. Vibrio cholerae ghosts (VCG) are nontoxic, effective delivery vehicles with potent adjuvant properties, and are capable of inducing both T cell and Ab responses in mucosal tissues. We investigated the hypothesis that rVCG could serve as effective delivery vehicles for single or multiple subunit chlamydial vaccines to induce a high level of protective immunity. rVCG-expressing chlamydial outer membrane proteins were produced by a two-step genetic process, involving cloning of Omp genes in V. cholerae, followed by gene E-mediated lysis of the cells. The immunogenicity and vaccine efficacy of rVCG-expressing single and multiple subunits were compared. Immunologic analysis indicated that i.m. immunization of mice with either vaccine construct induced a strong mucosal and systemic specific Th1 response against the whole chlamydial organism. However, there was an immunogenic advantage associated with the multiple subunit vaccine that induced a higher frequency of Th1 cells and a relatively greater ability to confer protective immunity, compared with the single subunit construct. These results support the operational theory that the ability of a vaccine to confer protective immunity against Chlamydia is a function of the level of Th1 response elicited.
This article has been cited by other articles:
|
|
 |
|
  A. Nunes, M. J. Borrego, B. Nunes, C. Florindo, and J. P. Gomes Evolutionary Dynamics of ompA, the Gene Encoding the Chlamydia trachomatis Key Antigen J. Bacteriol., December 1, 2009; 191(23): 7182 - 7192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Yu, X. Jiang, C. Shen, K. P. Karunakaran, and R. C. Brunham Novel Chlamydia muridarum T Cell Antigens Induce Protective Immunity against Lung and Genital Tract Infection in Murine Models J. Immunol., February 1, 2009; 182(3): 1602 - 1608. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Murthy, J. P. Chambers, P. A. Meier, G. Zhong, and B. P. Arulanandam Intranasal Vaccination with a Secreted Chlamydial Protein Enhances Resolution of Genital Chlamydia muridarum Infection, Protects against Oviduct Pathology, and Is Highly Dependent upon Endogenous Gamma Interferon Production Infect. Immun., February 1, 2007; 75(2): 666 - 676. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Fadel and A. Eley Chlamydia trachomatis OmcB protein is a surface-exposed glycosaminoglycan-dependent adhesin J. Med. Microbiol., January 1, 2007; 56(1): 15 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Sharma, Y. Zhong, F. Dong, J. M. Piper, G. Wang, and G. Zhong Profiling of Human Antibody Responses to Chlamydia trachomatis Urogenital Tract Infection Using Microplates Arrayed with 156 Chlamydial Fusion Proteins Infect. Immun., March 1, 2006; 74(3): 1490 - 1499. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
